Loading
Labcorp Holdings Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Caveney Brian J, was filed 13 Sept 2022.
Insider Decl.
1,283
Thresholds
n/a
Buy Volume
€920,902
7 ops. · all time
Sell Volume
€180M
225 ops. · all time
Who traded when
BuySalePeter J. Wilkinson8 sales
Schechter Adam H7 sales
Kerrii B. Anderson6 sales
van der Vaart Sandra D5 sales
Meltzer Jonathan C4 sales
Summy Amy B.3 sales
+5 other insiders
Since the insiders bought
- +6.3%Entry US$191.55 · Close at T+365 US$203.64
- -7.2%Entry US$228.97 · Close at T+365 US$212.47
- +69.7%Entry US$139.82 · Close at T+365 US$237.29
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Labcorp Holdings Inc. Buy (bullish), based on 16 analysts. Average price target: US$345.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,870 of 26,280 companies
49.9
score / 100
Value49
Quality51
FCF yld4.6%
Earn yld3.3%
EV/EBITDA16.3x
ROE12%
Gross mgn29%
Net mgn6.3%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$323.75
Analyst consensus
16 analystsBuy
US$293.00Target US$345.13(+7%)US$385.00
Income statement
RevenueUS$14B
Gross profitUS$4B29% margin
EBITDAUS$2B14% margin
Net incomeUS$876.5M7.0% margin
Valuation
PER (trailing)26.8x
PER (forward)16.4x
P/Book3.0x
Beta0.85
Balance sheet & cash
Market capUS$26.3B
Total debtUS$6.5B
Free Cash FlowUS$1.2B
Debt / Equity79%
Profitability & ownership
ROE11.7%
ROA5.5%
% insiders0.3%
% institutions101.6%
Last declaration on 18 August 2026
Declarations1,283 total
3,000 shares@ US$318.020.0037% mcap32.6% of flowCommon StockSEC:0000920148-26-000186:0
3,000 shares@ US$318.130.0037% mcap100.0% of flowCommonSEC144:0001950047-26-008239
4,669 shares@ US$320.370.0059% mcap11.3% of flowCommonSEC144:0001959173-26-005865
82 shares@ US$309.220.0001% mcap2.2% of flowCommon StockSEC:0000920148-26-000172:0
1,338 shares@ US$209.250.0011% mcap24.7% of flowCommon StockSEC:0000920148-26-000172:1
1,338 shares@ US$309.23110.0016% mcap36.6% of flowCommon StockSEC:0000920148-26-000172:2
924 shares@ US$306.740.0011% mcap26.0% of flowCommonSEC144:0001959173-26-005587
73 shares@ US$283.880.0001% mcap8.4% of flowCommon StockSEC:0000920148-26-000152:1
93 shares@ US$283.880.0001% mcap28.4% of flowCommon StockSEC:0000920148-26-000151:1
256 sharesCommon StockSEC:0000920148-26-000152:0
327 sharesCommon StockSEC:0000920148-26-000151:0
92 shares@ US$286.190.0001% mcap10.7% of flowCommonSEC144:0001959173-26-005051
234 shares@ US$286.190.0003% mcap71.6% of flowCommonSEC144:0001959173-26-005039
7,138 shares@ US$280.480.0080% mcap47.8% of flowCommonSEC144:0001959173-26-004983
762 shares@ US$263.890.0009% mcap80.9% of flowCommonSEC144:0001959173-26-004412
451 shares@ US$268.3844.0% of flowCommon StockSEC:0000920148-26-000121:1
2,968 shares0Common StockSEC:0000920148-26-000124:2
1,986 shares0Common StockSEC:0000920148-26-000123:2
755 shares@ US$268.383.3% of flowCommon StockSEC:0000920148-26-000122:1
1,633 shares@ US$267.057.1% of flowCommon StockSEC:0000920148-26-000122:2
2,722 shares@ US$268.384.7% of flowCommon StockSEC:0000920148-26-000120:1
4,600 shares@ US$268.388.0% of flowCommon StockSEC:0000920148-26-000124:1
1,468 shares@ US$268.382.6% of flowCommon StockSEC:0000920148-26-000124:3
1,836 shares@ US$268.389.8% of flowCommon StockSEC:0000920148-26-000119:1
481 shares@ US$268.3817.1% of flowCommon StockSEC:0000920148-26-000115:1
25 of 1283 declarations
About Labcorp Holdings Inc.
At Labcorp Holdings Inc., the sales by David P. King, President & CEO, dominate: EUR 17,480,531 on September 5, 2017, then EUR 8,311,574 and EUR 8,203,347, both on June 13, 2016. The record's 225 sales come to EUR 179.6 million, with a median of EUR 268,667.
There are 7 purchases, worth EUR 920,902 (median EUR 48,802), 3% of open-market trades. The three largest are by Peter M. Neupert, Director, all on February 16, 2022: EUR 371,908, EUR 300,882 and EUR 139,777.
Read moreShow less
Glenn A. Eisenberg, Executive Vice President, is the top filer with 135 filings, 29 of them sales, ahead of Lance Berberian, EVP, Special Advisor, Strategy (100), Mark S. Schroeder, EVP, Pres Diagnostics & COO (95) and Sandra D. van der Vaart, EVP, Corporate Affairs (93).
The record holds 1,283 filings, published from January 12, 2016 to August 18, 2026, including 518 grants and 513 option exercises. Annual volume ranges from 96 in 2016 to 145 in 2026. Last twelve months: 151 filings, 15 sales, no purchase. The US healthcare company is listed on Nasdaq, worth USD 26.3 billion, with 44 filers and 0.3% of the capital held by insiders.
